After losing three top executives earlier this month, Dentsply Sirona Inc. named two people to leadership roles and announced the resignation of a third.
The York-based dental products manufacturer named Nick Alexos executive vice president and chief administrative officer, and Keith Ebling as executive vice president, general counsel and secretary.
Both will report to interim CEO Mark Thierer, who is filling in after the resignation of former CEO Jeffrey T. Slovin.
Ebling replaces Jonathan Friedman, who resigned last week as Dentsply’s senior vice president, secretary and general counsel.
Other recent departures from Dentsply include former executive chairman Bret W. Wise and COO Christopher T. Clark.
The company has described the executive reshuffling as designed to help the company reach its potential. Dentsply Sirona formed in 2016 from a merger between Dentsply International Inc. and Sirona Dental Systems Inc.
As chief administrative officer, Alexos will lead treasury, IT, business development, strategic planning and investor relations.
He worked most recently with Madison Dearborn Partners LLC, a Chicago-based private equity firm which he co-founded. Prior to that, he was with First Chicago Venture Capital and the First National Bank of Chicago. He is a CPA and received his MBA from The University of Chicago Booth School of Business.
“Nick will be an outstanding leader and business partner focusing on capital deployment, operating leverage expansion and potential acquisitions,” Theirer said in a statement.
Ebling comes to Dentsply Sirona from Express Scripts Holding Co., a pharmacy benefit management firm. He served in a number of legal and leadership roles over his nearly 20 years with the company, most recently as executive vice president and general counsel. An attorney, he has an MBA from Washington University Olin School of Business.
“We are fortunate to have someone with Keith’s expertise to guide us from a legal perspective as we position Dentsply Sirona for growth,” Theirer said in a statement.
Dentsply Sironia posted revenue of nearly $1.9 billion for the first six months of 2017, up from $1.8 billion for the same period in 2016, according to its most recent quarterly filing with the U.S. Securities and Exchange Commission.
Net income, however, slid from a gain of $231.2 million to a loss of $990.6 million, driven largely by a $1.1 billion charge in second quarter 2017 for goodwill impairment.